Literature DB >> 11328367

Beneficial effect of Helicobacter pylori eradication in dermatologic diseases.

A Shiotani1, K Okada, K Yanaoka, H Itoh, S Nishioka, M Sakurane, M Matsunaka.   

Abstract

BACKGROUND: A relationship between skin diseases, particularly rosacea and chronic urticaria, and H. pylori infection has been suggested.
METHODS: We preformed a prospective evaluation of the effect of H. pylori eradication in patients with a variety of chronic skin diseases. Patients were followed monthly for at least one year after cure of the infection. The effect of therapy was scored using a three point scale: complete remission (> 90% improvement), partial remission (50-90% improvement) or no improvement (< 50 improvement). The relationship between response and anti-H. pylori Ig G and E to specific H. pylori antigens was analyzed by Western blot analysis.
RESULTS: Eighty-eight H. pylori-infected patients with skin disease were enrolled. Treatment was successful in 73% of patients with chronic urticaria as 23% (6 of 26) had complete and 50% had partial remission. Sixty-two percent (18 of 29) with pruritus cutaneus had partial remission as well as 30% with prurigo chronica multiformis had complete remission. Western blotting was done on 24 patients with skin disease and a 44K H. pylori antigen was detected by Ig E analysis in 100% (5 of 5) patients with complete remission compared to 23% (3 of 13) in those without skin disease.
CONCLUSIONS: These results suggest it may be prudent to test patients with chronic urticaria, prurigo chronica multiformis, pruritus cutaneus, and eczema nummulare for H. pylori infection and to eradicate the infection in those whose test is positive.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328367     DOI: 10.1046/j.1523-5378.2001.00009.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  14 in total

Review 1.  Overview: Helicobacter pylori and extragastric disease.

Authors:  Hidekazu Suzuki; Barry James Marshall; Toshifumi Hibi
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

Review 2.  Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment.

Authors:  Traci L Testerman; James Morris
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 3.  [Infections and chronic spontaneous urticaria. A review].

Authors:  B Wedi; U Raap; D Wieczorek; A Kapp
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

4.  Helicobacter pylori infection in patients with selective immunoglobulin E deficiency.

Authors:  Eli Magen; Menachem Schlesinger; Itzhak Ben-Zion; Daniel Vardy
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 5.  Helicobacter pylori and skin autoimmune diseases.

Authors:  Eli Magen; Jorge-Shmuel Delgado
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 6.  An overview of chronic urticaria.

Authors:  Vincent S Beltrani
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

Review 7.  Helicobacter pylori: present status and future prospects in Japan.

Authors:  Hidekazu Suzuki; Toshifumi Hibi; Barry James Marshall
Journal:  J Gastroenterol       Date:  2007-02-16       Impact factor: 7.527

8.  Increases in Nonspecific Immunoglobulin E and Eosinophils after H. pylori Eradication.

Authors:  Yoshihiro Matsukawa; Yasuhiro Gon; Akihiro Hemmi; Jin Takeuchi; Shigemasa Sawada; Izumi Hayashi
Journal:  Case Rep Gastroenterol       Date:  2010-02-03

9.  Helicobacter pylori immunization and atopic dermatitis in South Italian children.

Authors:  Marcella Pedullà; Vincenzo Fierro; Ester Del Tufo; Rossella Alfano; Maria Triassi; Laura Perrone
Journal:  United European Gastroenterol J       Date:  2014-08       Impact factor: 4.623

10.  Urticaria and infections.

Authors:  Bettina Wedi; Ulrike Raap; Dorothea Wieczorek; Alexander Kapp
Journal:  Allergy Asthma Clin Immunol       Date:  2009-12-01       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.